Bellecapital International Ltd. cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 40.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,035 shares of the biopharmaceutical company's stock after selling 3,415 shares during the period. Bellecapital International Ltd.'s holdings in Gilead Sciences were worth $564,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. Newbridge Financial Services Group Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter worth $33,000. Annis Gardner Whiting Capital Advisors LLC increased its position in shares of Gilead Sciences by 158.8% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 216 shares during the period. Morton Brown Family Wealth LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $35,000. Whipplewood Advisors LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $35,000. Finally, Synergy Investment Management LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $40,000. 83.67% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the company. Oppenheimer cut their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a "hold" rating to a "buy" rating and upped their target price for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Cantor Fitzgerald assumed coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. Wells Fargo & Company increased their price target on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Finally, Morgan Stanley increased their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $110.55.
View Our Latest Stock Analysis on GILD
Gilead Sciences Price Performance
Shares of GILD stock traded down $2.07 during mid-day trading on Friday, hitting $109.98. 8,148,740 shares of the stock were exchanged, compared to its average volume of 7,744,306. The firm has a fifty day moving average of $105.67 and a 200 day moving average of $102.33. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52-week low of $62.69 and a 52-week high of $119.96. The company has a market cap of $136.81 billion, a PE ratio of 297.24, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the prior year, the firm earned ($1.32) EPS. The company's revenue for the quarter was down .3% on a year-over-year basis. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.87%. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.
Insider Buying and Selling
In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the transaction, the chief executive officer now directly owns 620,268 shares of the company's stock, valued at $68,489,992.56. This trade represents a 1.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the completion of the transaction, the chief financial officer now directly owns 165,674 shares in the company, valued at $16,537,578.68. This trade represents a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 43,000 shares of company stock worth $4,630,310 in the last 90 days. Insiders own 0.27% of the company's stock.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
